Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

기사 요약

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.